These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35129210)

  • 41. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
    Manly JJ; Glymour MM
    JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
    [No Abstract]   [Full Text] [Related]  

  • 43. The Search for a Drug to End Alzheimer's.
    Campbell S
    IEEE Pulse; 2021; 12(2):2-7. PubMed ID: 33861693
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medicare and the Shocking US Food and Drug Administration Approval of Aducanumab: Crisis or Opportunity?
    Crosson FJ; Covinsky K; Redberg RF
    JAMA Intern Med; 2021 Oct; 181(10):1278-1280. PubMed ID: 34254992
    [No Abstract]   [Full Text] [Related]  

  • 45. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
    Yigit V; Kalender S; Cetinturk I
    Cost Eff Resour Alloc; 2023 Aug; 21(1):51. PubMed ID: 37559042
    [TBL] [Abstract][Full Text] [Related]  

  • 47. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
    Planche V; Villain N
    JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
    [No Abstract]   [Full Text] [Related]  

  • 48. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    Emanuel EJ
    JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184
    [No Abstract]   [Full Text] [Related]  

  • 49. Aducanumab: First Approval.
    Dhillon S
    Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FDA's dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps.
    Rizk JG; Lewin JC
    BMJ Evid Based Med; 2023 Apr; 28(2):78-82. PubMed ID: 35450946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
    Gleason A; Ayton S; Bush AI
    Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902
    [No Abstract]   [Full Text] [Related]  

  • 52. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 53. Aducanumab and the Business of Alzheimer Disease-Some Choice.
    Karlawish J
    JAMA Neurol; 2021 Nov; 78(11):1303-1304. PubMed ID: 34410302
    [No Abstract]   [Full Text] [Related]  

  • 54. The Problem of Aducanumab for the Treatment of Alzheimer Disease.
    Alexander GC; Karlawish J
    Ann Intern Med; 2021 Sep; 174(9):1303-1304. PubMed ID: 34138642
    [No Abstract]   [Full Text] [Related]  

  • 55. What Might Aducanumab Teach Us About Clinicians' Judgment About Whether to Recommend Emerging Alzheimer's Interventions?
    Burroughs AW; Krain LP
    AMA J Ethics; 2023 Oct; 25(10):E777-782. PubMed ID: 37801063
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (AduhelmTM) to Patients Participating in Clinical Trials.
    Cummings J
    J Prev Alzheimers Dis; 2022; 9(2):241-246. PubMed ID: 35542996
    [No Abstract]   [Full Text] [Related]  

  • 57. Update: FDA approval of Biogen's aducanumab.
    Hollmann P
    Geriatr Nurs; 2022; 43():318-319. PubMed ID: 34996638
    [No Abstract]   [Full Text] [Related]  

  • 58. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
    Zissimopoulos J; Jacobson M; Chen Y; Borson S
    JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 60. Research-informed evidence and support for road safety legislation: findings from a national survey.
    Smith KC; Debinski B; Pollack K; Vernick J; Bowman S; Samuels A; Gielen A
    Accid Anal Prev; 2014 Dec; 73():109-15. PubMed ID: 25215926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.